Novartis NVS announced that the European Commission (EC) has approved Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]).It was granted ...
Basel, December 8, 2016 - Novartis today announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with ...
Smart inhaler tech company Propeller Health is collaborating with Novartis to bring its add-on sensor to its dry powder Breezhaler inhalers. Propeller's simple clip on sensor attaches to most asthma ...
Two Phase III studies demonstrated efficacy benefits of combining once-daily Onbrez Breezhaler 150 mcg with tiotropium in patients with COPD[1],[2] INTRUST 1 and 2 studies add to comprehensive data ...
European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with ...
Phase III INSIST study shows once-daily Onbrez Breezhaler gave better 24-hour bronchodilation than twice-daily salmeterol[1], a current mainstay of treatment Data show Onbrez Breezhaler significantly ...
Enerzair® Breezhaler® plus sensor is the first asthma medication to be co-packaged and co-prescribed with a digital health platform MADISON, Wis.--(BUSINESS WIRE)--Propeller Health today announced a ...
New analysis shows high-dose, once-daily Enerzair Breezhaler cut asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose A high dose of Novartis’ Enerzair Breezhaler ...
Vectura and Sosei Heptares exclusively licensed glycopyrronium bromide and certain intellectual property relating to its use and formulation to Novartis in April 2005. Novartis is responsible for the ...
Phase III studies show once-daily Onbrez Breezhaler plus tiotropium improved lung function (measured by trough FEV1) by up to 230 mL from baseline[1] Reported incidence of side effects was similar in ...
Novartis NVS announced that the European Commission (EC) has approved Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]).It was granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results